We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FibroGen Admits to Submitting False Heart Safety Data to FDA for Anemia Drug
FibroGen Admits to Submitting False Heart Safety Data to FDA for Anemia Drug
FibroGen admitted that it provided manipulated heart safety data to the FDA for its experimental oral anemia drug, roxadustat, throwing doubts over its potential approval as a treatment for anemia linked to chronic kidney disease (CKD).